REPL Quote, Financials, Valuation and Earnings

CorMedix, Inc. has a net margin of -- compared to Replimune Group, Inc.'s net margin of 49.9%. Replimune Group, Inc.'s return on equity of -82.53% beat CorMedix, Inc.'s return on equity of 95.25%.

Replimune Group, Inc. has a consensus price target of $12.57, signalling upside risk potential of 24.59%. On the other hand CorMedix, Inc. has an analysts' consensus of $19.00 which suggests that it could grow by 55.87%. Given that CorMedix, Inc. has higher upside potential than Replimune Group, Inc., analysts believe CorMedix, Inc. is more attractive than Replimune Group, Inc..

Replimune Group, Inc. has a beta of 0.659, which suggesting that the stock is 34.125% less volatile than S&P 500. In comparison CorMedix, Inc. has a beta of 1.322, suggesting its more volatile than the S&P 500 by 32.155%.

Replimune Group, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CorMedix, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Replimune Group, Inc. pays -- of its earnings as a dividend. CorMedix, Inc. pays out -- of its earnings as a dividend.

Replimune Group, Inc. quarterly revenues are --, which are smaller than CorMedix, Inc. quarterly revenues of $104.3M. Replimune Group, Inc.'s net income of -$83.1M is lower than CorMedix, Inc.'s net income of $108.6M. Notably, Replimune Group, Inc.'s price-to-earnings ratio is -- while CorMedix, Inc.'s PE ratio is 5.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Replimune Group, Inc. is -- versus 4.10x for CorMedix, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Olema Pharmaceuticals, Inc. has a net margin of -- compared to Replimune Group, Inc.'s net margin of --. Replimune Group, Inc.'s return on equity of -82.53% beat Olema Pharmaceuticals, Inc.'s return on equity of -45.61%.

Replimune Group, Inc. has a consensus price target of $12.57, signalling upside risk potential of 24.59%. On the other hand Olema Pharmaceuticals, Inc. has an analysts' consensus of $46.00 which suggests that it could grow by 67.58%. Given that Olema Pharmaceuticals, Inc. has higher upside potential than Replimune Group, Inc., analysts believe Olema Pharmaceuticals, Inc. is more attractive than Replimune Group, Inc..

Replimune Group, Inc. has a beta of 0.659, which suggesting that the stock is 34.125% less volatile than S&P 500. In comparison Olema Pharmaceuticals, Inc. has a beta of 1.870, suggesting its more volatile than the S&P 500 by 86.967%.

Replimune Group, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Olema Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Replimune Group, Inc. pays -- of its earnings as a dividend. Olema Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Replimune Group, Inc. quarterly revenues are --, which are smaller than Olema Pharmaceuticals, Inc. quarterly revenues of --. Replimune Group, Inc.'s net income of -$83.1M is lower than Olema Pharmaceuticals, Inc.'s net income of -$42.2M. Notably, Replimune Group, Inc.'s price-to-earnings ratio is -- while Olema Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Replimune Group, Inc. is -- versus -- for Olema Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Rapt Therapeutics, Inc. has a net margin of -- compared to Replimune Group, Inc.'s net margin of --. Replimune Group, Inc.'s return on equity of -82.53% beat Rapt Therapeutics, Inc.'s return on equity of -67.79%.

Replimune Group, Inc. has a consensus price target of $12.57, signalling upside risk potential of 24.59%. On the other hand Rapt Therapeutics, Inc. has an analysts' consensus of $65.00 which suggests that it could grow by 81.36%. Given that Rapt Therapeutics, Inc. has higher upside potential than Replimune Group, Inc., analysts believe Rapt Therapeutics, Inc. is more attractive than Replimune Group, Inc..

Replimune Group, Inc. has a beta of 0.659, which suggesting that the stock is 34.125% less volatile than S&P 500. In comparison Rapt Therapeutics, Inc. has a beta of 0.428, suggesting its less volatile than the S&P 500 by 57.168%.

Replimune Group, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rapt Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Replimune Group, Inc. pays -- of its earnings as a dividend. Rapt Therapeutics, Inc. pays out -- of its earnings as a dividend.

Replimune Group, Inc. quarterly revenues are --, which are smaller than Rapt Therapeutics, Inc. quarterly revenues of --. Replimune Group, Inc.'s net income of -$83.1M is lower than Rapt Therapeutics, Inc.'s net income of -$17.6M. Notably, Replimune Group, Inc.'s price-to-earnings ratio is -- while Rapt Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Replimune Group, Inc. is -- versus 54.16x for Rapt Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Verastem, Inc. has a net margin of -- compared to Replimune Group, Inc.'s net margin of -876.34%. Replimune Group, Inc.'s return on equity of -82.53% beat Verastem, Inc.'s return on equity of -1773.4%.

Replimune Group, Inc. has a consensus price target of $12.57, signalling upside risk potential of 24.59%. On the other hand Verastem, Inc. has an analysts' consensus of $16.00 which suggests that it could grow by 103.3%. Given that Verastem, Inc. has higher upside potential than Replimune Group, Inc., analysts believe Verastem, Inc. is more attractive than Replimune Group, Inc..

Replimune Group, Inc. has a beta of 0.659, which suggesting that the stock is 34.125% less volatile than S&P 500. In comparison Verastem, Inc. has a beta of 0.412, suggesting its less volatile than the S&P 500 by 58.798%.

Replimune Group, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Verastem, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Replimune Group, Inc. pays -- of its earnings as a dividend. Verastem, Inc. pays out -- of its earnings as a dividend.

Replimune Group, Inc. quarterly revenues are --, which are smaller than Verastem, Inc. quarterly revenues of $11.2M. Replimune Group, Inc.'s net income of -$83.1M is higher than Verastem, Inc.'s net income of -$98.5M. Notably, Replimune Group, Inc.'s price-to-earnings ratio is -- while Verastem, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Replimune Group, Inc. is -- versus 36.78x for Verastem, Inc.. Usually stocks with elevated PS ratios are considered overvalued.